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Abstract
Background: More than 1.2 million people in the United States are living with human immunodeficiency virus (HIV),
and 3.2 million are living with hepatitis C virus (HCV). An estimated 25 % of persons living with HIV also have HCV. It is
therefore of great public health importance to ensure the prompt diagnosis of both HIV and HCV in populations that
have the highest prevalence of both infections, including individuals with substance use disorders (SUD).
Methods/design: In this theory-driven, efficacy-effectiveness-implementation hybrid study, we will develop and test
an on-site bundled rapid HIV/HCV testing intervention for SUD treatment programs. Its aim is to increase the receipt of
HIV and HCV test results among SUD treatment patients. Using a rigorous process involving patients, providers, and
program managers, we will incorporate rapid HCV testing into evidence-based HIV testing and linkage to care
interventions. We will then test, in a randomized controlled trial, the extent to which this bundled rapid HIV/HCV
testing approach increases receipt of HIV and HCV test results. Lastly, we will conduct formative research to understand
the barriers to, and facilitators of, the adoption, implementation, and sustainability of the bundled rapid testing strategy
in SUD treatment programs.
Discussion: Novel approaches that effectively integrate on-site rapid HIV and rapid HCV testing are needed to address
both the HIV and HCV epidemics. If feasible and efficacious, bundled rapid HIV/HCV testing may offer a scalable,
potentially cost-effective approach to testing high-risk populations, such as patients of SUD treatment programs. It may
ultimately lead to improved linkage to care and progress through the HIV and HCV care and treatment cascades.
Trial registration: ClinicalTrials.gov: NCT02355080. (30 January 2015)
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Background
More than 1.2 million people in the United States are
living with HIV, with an estimated 50,000 persons newly
infected each year [1]. Approximately 3.2 million people
are chronically infected with HCV [2, 3]. HIV/HCV co-
infection is common: up to 25 % of the people infected
with HIV in the US also have HCV [4, 5]. The preva-
lence of HIV and HCV in the US is particularly high
among persons with substance use disorders (SUDs).
Approximately, 25 % of HIV/AIDS cases are directly or
indirectly related to injection drug use, [6] and the
prevalence of HCV among people who inject drugs
(PWID) ranges from 35 to 65 % [2, 7, 8]. HIV and HCV
are also common among persons who use but do not in-
ject drugs (for example, intranasal use of cocaine or her-
oin) [9]. Among those infected with HIV and/or HCV,
significant numbers of people are not aware of their infec-
tion and are 1) more likely to transmit infection(s); 2) less
likely to benefit from early treatment; and 3) more prone
to morbidity, mortality, and complications due to co-
infection [10–12]. The Centers for Disease Control and
Prevention (CDC) recommend routine HIV and HCV
testing for people with a history of drug use [13–15].
The availability of both HIV and HCV testing in SUD
treatment programs is limited. Fewer than half of U.S.
SUD treatment programs offer HIV testing on-site to
their patients [10, 16–20]. The availability of on-site
HCV testing even declined from 53 % in 2005 to 34 %
in 2011 in opioid treatment programs [21]. The limited
availability of on-site testing is related to gaps in the cap-
acity of SUD treatment programs to conduct laboratory-
based HIV or HCV testing. [18, 22] In recent years,
SUD treatment programs have increasingly offered off-site
referrals for HIV and/or HCV testing to their patients, in-
stead of incurring large fixed costs required to make
laboratory-based HIV testing available on-site [23, 24]. In
addition, laboratory-based HIV or HCV testing methods
do not produce immediate results, and thus require pa-
tients to return to the clinic for their test results. Unfortu-
nately, few patients follow up on referrals for off-site
testing [24, 25] or return for their test results [26–29].
Rapid testing assays, introduced more than 10 years
ago for HIV and in 2010 for HCV, have the potential to
address several of these barriers to the scale up of HIV/
HCV testing in SUD treatment programs [30–32]. Rapid
tests for HIV and HCV use blood from a finger stick or
oral fluid from a swab and can be conducted under a
Clinical Laboratory Improvement Agreement (CLIA)
Certificate of Waiver. [33] They do not require extensive
laboratory facilities and can be performed without a doc-
tor, nurse, or phlebotomist. They are also highly accurate
[26, 31, 34] and yield preliminary results in no more
than 20 minutes, which allows testing and result notifi-
cation to occur during the same visit.
Despite several calls for the integration of HIV and
HCV services [35–41], SUD treatment programs have
not yet adopted a rapid HIV/HCV testing “bundle” for
several reasons [26]. First, offering both tests might be
time consuming for staff that already faces a significant
workload. Offering on-site bundled HIV/HCV testing
thus requires streamlined testing procedures to facilitate
integration and reduce constraints on service delivery.
Second, some patients may become particularly dis-
tressed if they learn that they are infected with both HIV
and HCV in the same visit. Post-test counseling proce-
dures adapted to the provision of bundled testing must
therefore be developed. Third, in the past, HCV treat-
ments were arduous, ineffective, and associated with ser-
ious side effects. The recent introduction of new, safe,
and highly efficacious treatment options for HCV ad-
dress these issues [42] and suggest that HCV testing
may now present significantly more clinical benefits to
patients. Fourth, treatments for HCV remain expensive.
However, increased access to health insurance through
the Affordable Care Act (ACA) [43] may present oppor-
tunities for increasing access to HCV treatment and care
for persons with SUDs who may have previously lacked
health insurance [44, 45].
Study objective
The overarching objective of this study is to develop and
test an on-site bundled rapid HIV and HCV testing strat-
egy to facilitate the timely diagnosis and receipt of test re-
sults for both HIV and HCV among persons with SUDs.
Methods/design
Study design
This efficacy-effectiveness-implementation hybrid study
consists of three distinct phases. Hybrid study designs
combine features of clinical trials, which examine the ef-
ficacy, effectiveness, and the implementation research,
which examines the adoption and sustainability of
service delivery processes [46, 47]. Hybrid designs are
postulated to advance the adoption and use of evidence-
based practices and enhance the potential benefits of
effective interventions [48–50]. In the “developmental
phase” of this study, we will produce a protocol for the
provision of on-site bundled rapid HIV/HCV testing in
SUD treatment programs. This will be followed by a
“trial” phase, during which we will test the efficacy of
the on-site bundled rapid HIV/HCV testing approach in
increasing receipt of HIV and HCV test results among
SUD patients. Finally, during a “translation” phase, we
will conduct formative research on the barriers and facil-
itators of the diffusion, adoption, implementation, and
sustainability of on-site bundled rapid HIV/HCV testing
in SUD treatment programs. Overall, we will develop
and evaluate the efficacy of the bundled rapid testing
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intervention and explore the preliminary effectiveness
and implementation considerations related to intervention
scale up. This study protocol follows the SPIRIT statement
(http://www.spirit-statement.org/spirit-statement/).
Conceptual/theoretical framework
To guide our approach to “bundling” the offer of on-site
rapid HIV and rapid HCV testing, we use an enhanced ver-
sion of ADAPT-ITT, [51–53] a framework used to transfer
evidence-based HIV interventions (HIV EBIs) to new rele-
vant populations. ADAPT-ITT builds on a sequence of
Assessment-Decision-Administration-Production-Topical
experts (ADAPT) -Integration-Training-Testing (ITT) and
culminates in a rigorous randomized controlled trial of the
impact of the newly developed intervention on short-term
outcomes (for example, receipt of HIV and HCV test re-
sults). Because we use ADAPT-ITT to add a multi-
infection component to existing HIV EBIs, rather than to
transfer EBIs across relevant populations, we modify some
of the framework’s procedures. The “decision” phase of
ADAPT-ITT is replaced by a “design” phase, during which
we will address key questions related to the structure and
content of the testing session. We also enhance the train-
ing component of the model by integrating a standardized
patients (SP) approach, an objective structured clinical
education procedure for training, evaluating and providing
feedback to providers to ensure the effective completion of
clinical tasks [54, 55].
To enable a broad scale up of on-site bundled HIV/
HCV testing, we add a final “translational” step to the
ADAPT-ITT process. We refer to this extended frame-
work as “ADAPT-IT3.” Our translational approach is
guided by a rich, interdisciplinary understanding of the
“Diffusion of Innovation” (DOI) theory outlined by
Rogers [56, 57]. DOI is defined as the process through
which an innovation is spread over time via communica-
tion (information, attitudes, etcetera) among members
of a social system (patients and organizations) [57]. The
goal of DOI is to advance an innovation from adoption,
through implementation, to routinizing [56, 58, 59].
Rogers describes two separate DOI processes: one for
organizations and another for individuals. This is in con-
trast to current practice in healthcare organizations,
where new interventions or services are often developed
solely by matching the proposed innovation to the work
needs and characteristics of its intended users [60]. DOI
theory, on the other hand, emphasizes the complexity of
communication channels and structural aspects of a so-
cial system in establishing the conditions that will favor
DOI. The details of the ADAPT-IT3 process are de-
scribed in Table 1, with the DOI framework for organi-
zations and individuals described in Table 2. We detail
the key steps of the implementation of the proposed ran-
domized controlled trial below.
Study facilities and setting
The study will be conducted at Promesa Inc. of the Acacia
Network, one of the largest community based SUD treat-
ment programs in the Bronx in New York City [61]. It has
the capacity to serve more than 1,700 patients at any point
in time across all of its facilities. We will include (1)
one facility, which provides methadone to abstinence
treatment to patients with opioid dependence (methadone-
to-abstinence ambulatory - MTAA). Methadone to abstin-
ence is a medical treatment protocol where methadone is
provided in gradually decreasing doses until the point of
abstinence. We will also include (2) one facility, which pro-
vides behavioral treatments (for example, cognitive behav-
ior approaches) to patients with addictions to opioids and
other types of drugs (chemical dependence outpatient pro-
gram – CDOP. Both MTAA and CDOP are co-located
with a federally qualified health center that provides pri-
mary healthcare services. The Primary Care Health Center
(PCHC) offers on-site laboratory-based enzyme immuno-
assay (EIA) HIV and HCV testing with delayed results.
SUD treatment patients who test positive for either HIV or
HCV are referred to relevant medical services. Typically,
patients choose to stay in the FQHC co-located with
MTAA and CDOP, but if they prefer, they can be referred
to another FQHC or primary care health center of their
choice.
Existing evidence-based rapid HIV testing interventions
Our starting point for the development of the on-site
bundled rapid HIV/HCV testing intervention is
grounded on existing HIV EBIs, which address testing
procedures and linkages to care. The rapid HIV testing
EBI we will adapt was shown to be highly effective in in-
creasing receipt of HIV test results compared to referral
for off-site HIV testing (80 % versus 18 %, respectively)
[25]. Patients in this EBI first receive verbal information
about the rapid HIV test, including a description of the
rapid testing procedure, timing for and meaning of test
results, and an explanation of the window period during
which an antibody test might be negative despite the
presence of HIV infection. Patients are then offered a
rapid HIV test [62]. Our approach to linkage to care ser-
vices will be based on a modified Anti-retroviral Treat-
ment and Access to Services (ARTAS) and Hepatitis C
Care Coordination Model (Hep-C CCM) [63–66].
ARTAS is an individual-level, multisession, time-limited
intervention with the goal of linking recently diagnosed
persons with HIV to medical care soon after receiving a
positive test result. ARTAS led to significantly higher link-
age to HIV care compared to a “passive referral” standard
of care [63, 64]. Hep-C CCM is a case manager-
coordinated service that links patients to primary care and
hepatology clinics. The intervention was efficacious in in-
creasing both attendance at HCV clinical evaluations and
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knowledge of HCV [65, 66]. The protocol for on-site bun-
dled rapid HIV/HCV testing will incorporate elements
from these interventions. It will be developed through
a combination of in-depth interviews, focus group
discussions, interactive testing, and expert consulta-
tions (see Table 1).
Study intervention
Patients randomized to the intervention group will thus
receive an offer to participate in on-site bundled rapid
HIV/HCV testing. Those who accept this offer will
receive pre-test information about testing procedures
and education, be tested and receive results during the
same visit as testing, and be provided post-test counsel-
ing and support services according to the protocol de-
veloped through our ADAPT-IT3 process. Patients with
reactive HIV and/or HCV antibody test results will be
actively linked immediately to a healthcare provider for
further evaluation and confirmatory testing (see Fig. 1).
Patients randomized to the control group will receive
the standard of care (SOC). The SOC is venipuncture
whole blood laboratory-based HIV and HCV testing with
Table 1 Study design and overview of approach to on-site bundled rapid HIV and HCV testing




(1) Assessment 30 to 40 10 to 14 3 to 5 Focus groups Focus group discussion with
patients and providers separately.




(2) Design n/a n/a n/a n/a Investigative team reviews
assessment data and then
devises preliminary approach
to developing and refining








Mock intervention is implemented
in front of selected patients and
providers (from step 1).
Draft protocol
0 of intervention
(4) Production n/a n/a n/a n/a Exit survey follows performance,




(5) Topical experts n/a n/a n/a n/a Investigative team incorporates
feedback from theater tests into
testing algorithm and manual,
develops quality assurance plan.
Draft protocol
1 of intervention
(6) Integration n/a n/a n/a n/a Integrate content from patient/








(8a) Testing (Pilot) 20 2 to 4 3 to 5 Exit interviews Pilot with patients who are
representative of target population.
Feedback through exit interviews
with patients, and feedback from
managers and providers who
observed the pilot. Produce draft
three based on pilot. Refresher
training, as appropriate, for program
and study staff on draft three
of the intervention protocol.
Draft protocol
3 of intervention
(8b) Testing (RCT) 239 2 to 4 3 to 5 Baseline + follow-up
assessments
Test draft three of the protocol




(TRANSLATION) (9) Translation 20 to 30 5 to 10 3- 5 Focus groups Elicit reactions of RCT participants.
Classify perceived barriers/facilitators
to acceptance of bundled rapid
testing, referral, and linkage services
(patients); and adoption of bundled
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delayed results (enzyme immunoassay). Patients may not
receive pre-test information, results, and post-test coun-
seling, especially if non-reactive or negative test result(s).
Linkage to care in the SOC is accomplished by referral
to a healthcare provider within the participating SUD
treatment organization or by passive referral to other
health facilities. After the end of the follow-up period
(see below), all patients in the control group will be of-
fered access to the on-site bundled rapid HIV/HCV test-
ing intervention. This will include all procedures (that is,
rapid HIV/HCV testing, post-test counseling, and link-
ages to care), as appropriate. Trained study staff will ob-
tain written informed consent from all patients prior to
enrollment. Additionally, trained supervisors will moni-
tor the safety and efficacy of the trial intervention on a
regular basis. They will ensure that all study procedures
are conducted and that data are generated, documented,
and reported in compliance with the protocol and ap-
plicable regulations.
Randomization
Participants will be assigned randomly to the interven-
tion or to the control group at the time of the baseline
visit. Randomization will be stratified by recruitment site
(MTAA versus CDOP programs), location of primary
care provider (study site versus other), and type of drug
use (injection as a method of drug use versus non-
injection drug use). The randomization will be done in
blocks of randomized size (varying from four to 10) with
computer-generated random numbers. This procedure
ensures that the distribution of treatment site and type
of drug use will be balanced across intervention and
control groups. It also prevents study staff from learning
the randomization pattern, which becomes obvious in a
fixed block-size scheme. The study statistician will gen-
erate the randomization lists, which will be concealed in
sequentially numbered, opaque, sealed envelopes with a
signature across the sealing point. Trained research as-
sistants, who are blind to the randomization schedule,
will provide the random assignment to participants at
the time of randomization.
Eligibility and recruitment
Participants must be (1) able and willing to provide in-
formed consent, (2) seeking or currently receiving SUD
treatment services (excluding alcohol only) at the par-
ticipating treatment programs, (3) at least 18 years old,
(4) able to communicate in English, (5) willing to sign a
release form that will allow medical record review (to
corroborate self-reports of receipt of test results), (6)
willing to provide locator information, (7) self report be-
ing HIV and HCV negative, or report not knowing their
Table 2 Diffusion of innovation: organization and individual patient level processes
Diffusion of innovation (on-site bundled rapid HIV/HCV testing
strategy) process in substance use disorders treatment programs
Innovation-decision process at the individual patient level
Stages Description Sample of questions guiding
each stage





challenges that create a
need to increase HIV/HCV
testing and receipt of test
results among patients
What is the primary motivation
to adopt a bundled rapid
testing strategy?
Knowledge Patients are introduced
to a bundled rapid
testing strategy but do
not have detailed
information about it
Patient knowledge of what
bundled rapid testing is, how
it works, and why it is
beneficial.




What problem or need in the
program matches a bundled
rapid testing strategy?
Persuasion To what extent are
patients interested in
bundled rapid testing,
linkage to care, and
further information?
Concerns of positive results
for one or both HIV/HCV,
timing and readiness to test,
apathy, and risk perceptions
Redefine/
restructure
Modifying a new testing




How would the program
operationalize the decision to
adopt bundled rapid testing?
How would structures be











treatment if HIV- and/or
HCV-positive
Clarifying Stabilizing of the relations
among the testing, post-





would the testing strategy
be reinvented, if at all?





concerns about test accuracy,
wait time for results, and
counseling
Routinizing Making bundled rapid
HIV/HCV testing, post-test
counseling, and linkage
services a normal part of
the organization’s activity.
Could bundled rapid testing
become part of a program’s
routine? What are the








may influence the decision
to use or not use the strategy
in the future
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HIV and HCV status, and (8) not have received results
of an HIV or HCV test initiated within the last
12 months. We will employ several recruitment strat-
egies to facilitate enrollment to reach our target sample
size, including trained research staff, posters, and collab-
orating with staff of the study site to identify interested
patients. We will promote participant retention by col-
lecting locator information, which will be used to con-
tact participants to remind them of follow-up visits and
to locate participants who cannot be reached. Participa-
tion in the study is voluntary, and participants may
choose to end their involvement at any time.
Study assessments
There will be three assessments during this trial of on-
site bundled rapid HIV/HCV testing. These will include a
baseline assessment administered prior to randomization,
a follow-up assessment conducted 1 month after
randomization, and a final assessment conducted
3 months after randomization (see Fig. 1).
Primary outcome
The primary outcome will be self-reported receipt of
HIV and HCV test results. The primary outcome will be
assessed one-month post-randomization. Our use of
self-reported receipt of test results is consistent with the
use of self-reports as the primary outcome for evaluating
rapid HIV testing interventions [25].
Secondary outcome and other study measures
We will also evaluate several secondary outcomes. These
will include an additional measure of receipt of test re-
sults based on medical records. Study participants will
complete release forms (as applicable) in order to grant
permission to study staff to review their medical records,
including HIV and HCV testing records. Other second-
ary outcomes will include self-reported sexual risk be-
haviors and drug use practices such as (i) counts of
unprotected vaginal and anal sex acts in the past
3 months with any sex partner, (ii) use of any drugs in
the past 3 months, and (iii) unsafe injection practices.
Additional measures will evaluate linkage to care by
measuring the proportion of patients who initiated HIV
care or HCV care before the 3-month follow-up among
those whose test results were positive for HIV and/or
HCV. Linkage to care for HIV or HCV will be measured
separately, to account for variations in barriers to
Chemical Dependence Outpatient Program 
(CDOP)
Methadone to Abstinence Ambulatory 
(MTAA)
Screening, consent and enrollment
ACASI Baseline
Randomization





Recruitment at MTAA and CDOP
Fig. 1 Flow diagram of the trial design: on-site bundled rapid HIV/HCV testing randomized controlled trial (RCT). The diagram illustrates the
progression of participants through the different points of the study
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initiating care, which may be greater for HCV than bar-
riers to initiating HIV medical care [67].
Data sources
In order to measure all outcomes, indicators, and covari-
ates, each study assessment will collect detailed data
from study participants. We will use audio computer-
assisted self-interview (ACASI) to limit social desirability
biases in reporting sensitive behaviors (for example, sex-
ual behaviors) [68]. Interviewers will be trained in the
use of the ACASI program and survey to assist respon-
dents as needed. To protect against the risk of loss of
confidentiality during and after the trial, all data will be
maintained on a password-protected local server. Study
datasets will be de-identified prior to analysis.
We will collect the following information:
Demographic characteristics of participants (at base-
line), which will include age, sex, race and ethnicity,
years of formal education, income, employment status,
health insurance, living arrangement including home-
lessness, number of children (under 18), and history
with the criminal justice system (that is, arrests and
incarcerations). This information will be used to de-
scribe the study sample, to assess for any differences
between intervention groups, and to test for selective
attrition.
Sexual behaviors: We will collect data on the total
number of sex partners in the past 3 months, total
number of vaginal sex partners and anal sex partners,
total number of unprotected vaginal and total number
of anal sex partners, and total acts of unprotected va-
ginal/anal sex.
Drug use: We will ask about the frequency, duration,
and amount of substance use, including alcohol, canna-
bis, methamphetamine, cocaine, heroin, club-drugs, and
mis-used prescription drugs. We will assess injection
drug use, including the types of drugs injected and the
sharing of needles and other drug paraphernalia (for ex-
ample, spoons and cotton balls). We will also ask about
overdoses and treatment for overdose (that is, the use of
naloxone). At baseline, we will measure these behaviors
over the 3 months before the interview. These measures
will be repeated at 1- and 3-month follow-ups, with ad-
justments to the recall period.
Utilization of drug treatment services: We will ask the
following three questions at baseline and at both follow-
up visits: (1) Are you in treatment right now? (2) What
treatment are you undergoing? (for example, detox) and
(3) How many days have you been in this treatment?
Linkage to medical care: We will also collect data on ini-
tiation of treatment among HIV and/or HCV positive pa-
tients, using the following questions: (1) Did you have an
appointment with a medical provider for HIV services? (2)
Did you have an appointment with a medical provider for
HCV services? (3) Number of medical appointments made
and appointments attended since the last interview, as
well as initiation of ART and HCV treatment?
Power and sample size
We designed the trial to estimate the effects of on-site bun-
dled rapid HIV/HCV testing on receipt of test results sep-
arately in each of the two types of SUD treatment facilities
(MTAA and CDOP). Based on preliminary data from the
study sites for the standard of care, we assumed that 50 %
of control group participants enrolled at the CDOP facility
will receive their HIV and HCV results after 1 month. We
assumed that 55 % of control group participants receive
their HIV and HCV test results after 1 month in the MTAA
program, which treats a higher proportion of PWIDs. Based
on findings from the evidence-based rapid HIV interven-
tion that informs this study [25], we assumed that 80 % of
patients in the intervention group would receive their HIV
and HCV test results within 1 month of randomization. To
detect such intervention effects on the basis of a two-
sample, chi-squared test for independent proportions with
80 % power and α = 0.05, we will require 78 patients in
CDOP and 108 patients in MTAA facilities. We assumed
an 80 % follow-up rate among participants enrolled at the
MTAA program. We assumed a slightly lower follow-up
rate among participants enrolled at the CDOP facility
(75 %) because adherence to behavioral SUD treatment is
lower among CDOP patients at Promesa Inc. These are
conservative assumptions. For example, during the trial of
the rapid HIV testing EBI, which informs this study, re-
searchers achieved a 98 % 1-month follow-up rate [25]. In
total, we obtained a total sample size of 239 participants
(104 in CDOP and 135 in MTAA).
Empirical analysis
The primary outcome is a categorical variable denoting
self-reported receipt of rapid HIV and rapid HCV test
results at 1-month post-randomization. We will use a
generalized estimating equation model, which includes
covariates for type of drug use (injection/non-injection)
and location of primary care provider (study site versus
elsewhere). The model will also include indicator vari-
ables for HIV/HCV testing intervention status and the
type of SUD treatment facility (MTAA versus CDOP),
where the participants were recruited. The primary test
of our study hypothesis will be a two-degree of freedom
test of significance of the intervention across the two
types of SUD treatment facilities. In post-hoc tests, the
efficacy and effect size in each type of SUD treatment fa-
cility will be examined. To do so, we will include an
interaction between variables identifying study groups
(intervention versus control) and type of SUD treatment
facility (MTAA versus CDOP). The primary analysis will
be intent-to-treat, where everyone is included in the study
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group to which they were randomized, regardless of re-
ceipt of intervention. In sensitivity analyses, participants
who have died or who have been lost to follow-up will be
counted as not having tested. We will adjust for baseline
covariates that may be associated with attrition from the
study sample using inverse probability reweighting proce-
dures as recommended for the GEE model [69].
The secondary outcomes related to linkage to HIV and
HCV care, as well as to drug use, are categorical vari-
ables. They will be analyzed using techniques similar to
those used for the primary outcome. This is also the case
for indicators related to HIV and HCV prevalence
among patients tested by bundled rapid testing versus
standard of care. The number of unprotected sex acts
over a period of time is a count variable and will be
modeled using Poisson or negative binomial regression
(if the variable is over-dispersed) or the zero-inflated
version of these if necessary. Type of drug use (injec-
tion/non-injection) and the recruitment site (MTAA or
CDOP) will be included as covariates. If other covariates
predict missing data, they will also be included as con-
trol variables. All analyses of secondary outcomes will
focus on the pooled data, that is, CDOP +MTAA pro-
grams. Because of the limited sample size, we will not
conduct formal mediation analyses.
Translation
We will conduct formative research on the barriers and
facilitators of the adoption, implementation, and sustain-
ability of on-site bundled rapid HIV/HCV testing in SUDs
treatment programs. To do so, we will collect qualitative
data from three groups: patients, providers, and program
managers who participated in the randomized trial. This
will consist of two focus group discussions (FGDs) with
each group, followed by a short questionnaire on individ-
ual perceptions. FGDs will be informed by an integrated
conceptual framework, derived from the “Diffusion of
Innovation” theory [56]. We will identify facilitators and
barriers to scaling-up the bundled rapid HIV/HCV strat-
egy, linking infected patients to medical care, and we will
develop strategies to address these barriers.
Ethics
The Columbia University Medical Center (CUMC) Institu-
tional Review Board (IRB) will provide ethical oversight for
the study. Ethical approval for this study has been granted
from the CUMC IRB (Protocol Number: IRB-AAAN5869).
Publications
The final results from the study will be submitted for pub-
lication in a peer-reviewed journal. We will also dissemin-
ate our findings to the study site and study population.
Discussion
This study is one of the first to systematically develop
and test an on-site bundled rapid HCV and rapid HIV
testing strategy, complemented with post-test counseling
and linkage to care services, to address the overlapping
HIV and HCV epidemics among persons with SUDs. It
is also novel in employing an efficacy-effectiveness-
implementation hybrid design. We hypothesize that the
bundled testing strategy will increase HIV and HCV test-
ing rates and knowledge of infection status among per-
sons with SUDs. On-site bundled rapid testing promises
significant benefits in terms of both HCV and HIV-
related outcomes. We anticipate that the bundled rapid
testing strategy will considerably increase HCV testing
rates among patients of SUD treatment programs, possibly
in proportions similar to those observed during the multi-
center trial of rapid HIV testing in such programs [25]. This
has the potential to increase HCV case finding and reduce
HCV transmission among patients of SUD treatment pro-
grams, through the adoption of safer injection and sexual
practices. It may also promote treatment initiation, particu-
larly in a context where numbers of patients may gain ac-
cess to health insurance through the Affordable Care Act
(ACA) and new, safe and effective treatments options for
HCV have become available [42–45].
Bundled rapid testing may also provide important bene-
fits in terms of HIV prevention and treatment. Since HIV
and HCV often transmitted in the same needle-sharing
and/or sexual networks, [70–77] testing positive for HCV
may serve as a) an early warning system that a person is at
a high risk of becoming infected with HIV and b) a system
to allow the delivery of intensified risk reduction interven-
tions and to encourage the adoption of protective behav-
iors (for example, needle exchange, partner reduction, and
PrEP). In addition, knowledge of HCV status may improve
clinical decisions related to HIV/AIDS care and treatment,
including earlier diagnosis of co-infection, improved pre-
vention of liver disease, and better management of side ef-
fects. The proposed study will address key barriers that
prevent the broad diffusion of bundled rapid testing, in-
cluding organizational and patient-level barriers, and pro-
vide preliminary data for future implementation research
on the adoption of evidence-based practices in SUD
treatment programs. In particular, it will yield insights
about a multicomponent, multilevel intervention de-
signed to foster the adoption and implementation of
bundled rapid testing in such settings.
Trial status
The trial is at the planning stage, with the first six
phases of the ADAPT-IT3 process already completed.
Recruitment of study participants is tentatively sched-
uled to commence in March 2016.
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Abbreviations
Table 3 World Health Organization trial registration data set
Item
number
Item Description Addressed on page
number
1 Primary registry and trial-
identifying number
Name of primary registry and the unique identifier assigned by the primary registry 2
2 Date of registration in
primary registry
Date when the trial was officially registered in the primary registry 2
3 Secondary identifying
numbers
Other identifiers, if any Universal Trial Number Identifiers assigned by the sponsor Other
trial registration numbers issued by other registries Identifiers issued by funding bodies,
collaborative research groups, regulatory authorities, ethics committees/institutional
review boards, etcetera.
Not applicable
4 Sources of monetary
or material support
Major sources of monetary or material support for the trial (for example, funding
agency, foundation, company, and institution)
12
5 Primary sponsor Person, organization, group, or other legal entity that takes responsibility for initiating
and managing a study
12
6 Secondary sponsor(s) Additional persons, organizations, or other legal persons, if any, who have agreed with
the primary sponsor to take on responsibilities of sponsorship
Not applicable
7 Contact for public queries E-mail address, telephone number, and postal address of the contact who will respond
to general queries, including information about current recruitment status
1
8 Contact for scientific
queries
Name and title, e-mail address, telephone number, postal address, and affiliation of
the principal investigator and e-mail address, telephone number, postal address, and
affiliation of the contact for scientific queries about the trial (if applicable)
1
9 Public title Title intended for the lay public in easily understood language 1
10 Scientific title Scientific title of the study as it appears in the protocol submitted for funding and
ethical review; include trial acronym, if available
Not applicable
11 Countries of recruitment Countries from which participants will be recruited 5
12 Health condition(s) or
problem(s) studied
Primary health condition(s) or problem(s) studied (for example, depression, breast
cancer, or medication error)
3
13 Intervention(s) For each group of the trial, record a brief intervention name plus an intervention
description name. For drugs, use the generic name; for other types of interventions,
provide a brief descriptive name of the intervention. This name must be sufficiently
detailed for it to be possible to distinguish between the groups of a study; for example,
interventions involving drugs may include dosage form, dosage, frequency, and duration
6
14 Key inclusion and exclusion
criteria
Inclusion and exclusion criteria for participant selection, including age and sex 7
15 Study type Method of allocation (randomized/nonrandomized) and blinding/masking (identify who
is blinded) Assignment (for example, single group, parallel, crossover, or factorial) and
purpose Phase (if applicable) For randomized trials - method of sequence generation
and allocation concealment
6 and 7
16 Date of first enrollment Anticipated or actual date of enrollment of the first participant 11
17 Target sample size Total number of participants to enroll 9
18 Recruitment status Pending - participants are not yet being recruited or enrolled at any site Recruiting
Suspended - temporary halt in recruitment and enrollment Complete - participants are
no longer being recruited or enrolled Other
11
19 Primary outcome(s) The primary outcome should be the outcome used in sample size calculations or the
main outcome used to determine the effects of the intervention For each primary
outcome, provide the following: Name of the outcome (do not use abbreviations) Metric
or method of measurement used (be as specific as possible)
7
Time point of primary interest
20 Key secondary outcome(s) As for primary outcomes, for each secondary outcome provide the following: Name
of the outcome (do not use abbreviations) Metric or method of measurement used
(be as specific as possible) Time point of interest
7 and 8
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ACA: Affordable Care Act; ADAPT-ITT: Assessment-Decision-Administration-
Production-Topical experts-Integration-Training-Testing; ADAPT-
IT3: Assessment-Design-Administration-Production-Topical experts-
Integration-Training-Testing-Translation; ARTAS: Anti-retroviral Treatment and
Access to Services; CDC: Centers for Disease Control and Prevention;
CDOP: chemical dependence outpatient program; CLIA: clinical laboratory
improvement agreement; DOI: diffusion of innovation; EBI: evidence-based
interventions; EIA: enzyme immunoassays; FQHC: federally qualified health
center; HCV: hepatitis C virus; Hep-C CCM: Hepatitis C Care Coordination
Model; HIV: human immunodeficiency virus; MTAA: methadone-to-
abstinence ambulatory; PrEP: pre-exposure prophylaxis; PWID: person who
injects drugs; RCT: randomized controlled trial; SOC: standard of care;
SP: standardized patients; SUD: substance use disorder..
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